Boston Private Wealth LLC Acquires Shares of 606 Charles River Laboratories International, Inc. (NYSE:CRL)

Boston Private Wealth LLC bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 606 shares of the medical research company’s stock, valued at approximately $250,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 644.4% in the second quarter. Assetmark Inc. now owns 67 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 58 shares during the last quarter. AdvisorNet Financial Inc purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at approximately $26,000. Wolff Wiese Magana LLC grew its position in shares of Charles River Laboratories International by 119.1% during the third quarter. Wolff Wiese Magana LLC now owns 103 shares of the medical research company’s stock worth $42,000 after buying an additional 56 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its stake in shares of Charles River Laboratories International by 314.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 145 shares of the medical research company’s stock worth $54,000 after buying an additional 110 shares during the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new stake in Charles River Laboratories International in the second quarter valued at $54,000. 91.64% of the stock is currently owned by institutional investors and hedge funds.

CRL has been the topic of a number of recent analyst reports. Citigroup cut their target price on shares of Charles River Laboratories International from $425.00 to $400.00 and set a “neutral” rating on the stock in a research note on Thursday, November 4th. Deutsche Bank Aktiengesellschaft upped their price objective on Charles River Laboratories International from $354.00 to $409.00 and gave the company a “buy” rating in a research note on Tuesday, November 16th. Morgan Stanley decreased their target price on Charles River Laboratories International from $480.00 to $465.00 and set an “overweight” rating for the company in a research report on Thursday, November 4th. Evercore ISI reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, October 14th. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Charles River Laboratories International in a report on Monday, December 20th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $415.50.

Shares of CRL opened at $355.01 on Friday. The firm has a fifty day moving average of $366.58 and a 200-day moving average of $397.38. The company has a market cap of $17.91 billion, a price-to-earnings ratio of 45.87, a price-to-earnings-growth ratio of 2.16 and a beta of 1.17. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.22 and a current ratio of 1.40. Charles River Laboratories International, Inc. has a 1 year low of $249.48 and a 1 year high of $460.21.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Tuesday, November 2nd. The medical research company reported $2.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 23.14%. The firm had revenue of $895.90 million for the quarter, compared to the consensus estimate of $902.03 million. During the same period last year, the firm posted $2.33 EPS. Charles River Laboratories International’s quarterly revenue was up 20.5% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 10.25 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

See Also: Beta

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.